Status: Not yet recruiting
Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.
Phase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101
Participants needed: 46
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Arovella Therapeutics LtdUpdated: Apr 8, 2026Locations: 3
Eligibility criteria
Over 18 years old [+6]
Prior anti-CD1d monoclonal antibody treatment [+16]